Synergy CHC Corp

Análisis de la acción Synergy CHC Corp (SNYR)

$0.091

-0.061 (-67.02%)Al cierre

Loading chart…
Máximo
0.157
Apertura
0.137
Precio medio ponderado por volumen
0.11
Volumen
70.12M
Capitalización
—
Mínimo
0.091
Importe
7.90M
EV/EBITDA, TTM
-8.03

Synergy CHC Corp. is a provider of consumer healthcare, beauty, and lifestyle products. The Company's brand portfolio includes FOCUSfactor and Flat Tummy. FOCUSfactor is a clinically studied brain health supplement and functional beverage line. Flat Tummy is a lifestyle brand that provides a suite of nutritional products to help women achieve their weight management goals. It has six additional, non-core brands are Hand MD is a complete hand-care brand to help maintain clean and healthy hands while reducing the signs of aging; Perfekt Beauty is in beauty line of products for the eyes, lips, brows, cheeks and skin; Sneaky Vaunt is in lingerie brand with a line of women’s shapewear, bralettes and panties; The Queen Pegasus is in eyelash enhancement products for longer, thicker, natural lashes; Neuragen is in fast-acting topical treatments for neuropathic (nerve) pain, and UrgentRx is in line of fast-acting, portable, powdered over-the-counter medications.

synergychc.com

Análisis de IA of Synergy CHC Corp (SNYR)

Vender

Synergy CHC Corp is not a good buy right now due to its poor financial performance and significant losses. The current price is $0.10, and the company reported a staggering net loss of $14.82 million in Q4 2025, which raises serious concerns about its sustainability. Additionally, the forward P/E ratio is 0.5347, indicating that the market is not optimistic about future earnings, and the stock has declined 94.65% year-to-date, reflecting a lack of investor confidence.

Métricas de valoración

El PER previsto actual de Synergy CHC Corp (SNYR) es 1.83, frente a su media de 5 años de 1.51.

PER previsto

Valor razonable
Media 5A P/E
1.51
P/E actual
1.83
Sobrevalorada
3.81
Infravalorada
-0.79

EV/EBITDA previsto

Infravalorado
Media 5A EV/EBITDA
1.43
EV/EBITDA actual
-8.03
Sobrevalorada
6.47
Infravalorada
-3.62

Precio/ventas previsto

Infravalorado
Media 5A P/S
0.34
P/S actual
0.04
Sobrevalorada
0.59
Infravalorada
0.09

Cronología de eventos

2026-08-21 (ET)

09:00:00

Synergy CHC Receives Compliance Notice from Nasdaq

2026-05-15 (ET)

17:10:00

Synergy CHC Files to Sell 101.71M Shares of Common Stock

2026-04-01 (ET)

09:20:00

Company Q4 Revenue Falls to $6.07M

2026-01-27 (ET)

08:10:00

Synergy CHC Expands FOCUSfactor Product Line in Canada

2025-12-16 (ET)

08:10:00

Synergy CHC Appoints Pedro Colmenares as Sales & Marketing Director for Mexico & Latin America

Noticias

Preguntas frecuentes sobre SNYR, respondidas por Alphio AI

Synergy CHC Corp. is a provider of consumer healthcare, beauty, and lifestyle products. The Company's brand portfolio includes FOCUSfactor and Flat Tummy. FOCUSfactor is a clinically studied brain health supplement and functional beverage line. Flat Tummy is a lifestyle brand that provides a suite of nutritional products to help women achieve their weight management goals. It has six additional, non-core brands are Hand MD is a complete hand-care brand to help maintain clean and healthy hands while reducing the signs of aging; Perfekt Beauty is in beauty line of products for the eyes, lips, brows, cheeks and skin; Sneaky Vaunt is in lingerie brand with a line of women’s shapewear, bralettes and panties; The Queen Pegasus is in eyelash enhancement products for longer, thicker, natural lashes; Neuragen is in fast-acting topical treatments for neuropathic (nerve) pain, and UrgentRx is in line of fast-acting, portable, powdered over-the-counter medications. It operates in the Healthcare sector.

Synergy CHC Corp is not a good buy right now due to its poor financial performance and significant losses. The current price is $0.10, and the company reported a staggering net loss of $14.82 million in Q4 2025, which raises serious concerns about its sustainability. Additionally, the forward P/E ratio is 0.5347, indicating that the market is not optimistic about future earnings, and the stock has declined 94.65% year-to-date, reflecting a lack of investor confidence.

Comunidad

Más ↗

Aún no hay publicaciones

Regístrate o inicia sesión para participar

Artículos relacionados

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empezar a operar